News & Events about Gossamer Bio Inc.
Shares of Gossamer Bio, Inc. (NASDAQ:GOSS Get Rating) have received a consensus rating of Hold from the fourteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six...
Gossamer Bio, Inc. (NASDAQ:GOSS Get Rating) CEO Faheem Hasnain bought 440,500 shares of the stock in a transaction that occurred on Wednesday, March 22nd. The shares were purchased at an average cost of $1.14 per share, with a total value of $502,170.00. Following the purchase, the chief executive ...
Gossamer Bio, Inc. (NASDAQ:GOSS Get Rating) HC Wainwright issued their FY2027 earnings estimates for Gossamer Bio in a research note issued to investors on Tuesday, March 21st. HC Wainwright analyst P. Trucchio anticipates that the company will earn ($0.59) per share for the year. HC...
Gossamer Bio (NASDAQ:GOSS Get Rating) had its price objective cut by investment analysts at Barclays from $2.00 to $1.50 in a note issued to investors on Tuesday, The Fly reports. The firm presently has an equal weight rating on the stock. Barclayss target price points to a potential upside of 35.14...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended...